Modeling the health and economic impact of scaling up monthly oral pre-exposure prophylaxis alone or alongside injectable Lenacapavir in Kenya and South Africa

IntroductionMonthly oral HIV pre-exposure prophylaxis (PrEP) such as MK-8527 offer promise as low-cost, self-administered options that are easily delivered through community-based platforms. Economic evaluations of MK-8527 either alone or alongside other long-acting (LA) PrEP products like lenacapavir are needed for informing HIV prevention strategies. MethodsWe adapted an agent-based network model, EMOD-HIV, to simulate LA-PrEP scale-up in South Africa and western Kenya from 2026-2035; scenarios evaluated MK-8527 alone, lenacapavir alone and combined strategies, with varying uptake among female sex workers, their male clients, and individuals with >1 partner. We assumed 95% effectiveness of MK-8527 for 2 months (assuming individuals took 2 of 3 pills dispensed) and 95% lenacapavir effectiveness for 6 months. Scenarios were compared to a baseline of daily oral PrEP only. ResultsAssuming the same uptake rates, MK-8527 alone achieved lower health impacts than lenacapavir alone in both settings (6-14% vs. 11-18% of HIV infections averted) but had substantially lower costs; provision costs of MK-8527 were 58-59% lower than lenacapavir assuming $1.00/pilland40-43$2.50/pill. In western Kenya, ICERs for MK-8527 alone were $467/DALYavertedand$799/DALY averted assuming pill prices of $1.00and$2.50 respectively, compared to $1,306/DALYavertedforlenacapavir.InSouthAfrica,allLA-PrEPstrategieswerecost-savingoverthe35-yearhorizon,althoughnear-termbudgetimpactsweresubstantial($169-348 million over five years). Service delivery accounted for the majority of MK-8527 costs (73% at $1.00perpill).CombinedstrategiesoflenacapavirandMK-8527increasedhealthbenefits(13-23$1.00 per pill) and provision is targeted to populations at substantial HIV risk.